- Home
- RDVT vs XNCR Comparison
RDVT vs XNCR Comparison
Compare RDVT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- XNCR
- Stock Information
- Founded
- RDVT 2017
- XNCR 1997
- Country
- RDVT United States
- XNCR United States
- Employees
- RDVT N/A
- XNCR N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- XNCR Health Care
- Exchange
- RDVT Nasdaq
- XNCR Nasdaq
- Market Cap
- RDVT 606.7M
- XNCR 547.8M
- IPO Year
- RDVT N/A
- XNCR 2013
- Fundamental
- Price
- RDVT $50.60
- XNCR $12.04
- Analyst Decision
- RDVT
- XNCR Buy
- Analyst Count
- RDVT 0
- XNCR 11
- Target Price
- RDVT N/A
- XNCR $22.20
- AVG Volume (30 Days)
- RDVT 95.0K
- XNCR 1.2M
- Earning Date
- RDVT 11-05-2025
- XNCR 11-05-2025
- Dividend Yield
- RDVT 0.59%
- XNCR N/A
- EPS Growth
- RDVT N/A
- XNCR N/A
- EPS
- RDVT 0.61
- XNCR N/A
- Revenue
- RDVT $82,399,000.00
- XNCR $146,929,000.00
- Revenue This Year
- RDVT $19.75
- XNCR $23.31
- Revenue Next Year
- RDVT $13.82
- XNCR N/A
- P/E Ratio
- RDVT $82.51
- XNCR N/A
- Revenue Growth
- RDVT 22.14
- XNCR N/A
- 52 Week Low
- RDVT $25.37
- XNCR $6.92
- 52 Week High
- RDVT $54.19
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- RDVT 52.64
- XNCR 80.54
- Support Level
- RDVT $49.91
- XNCR $10.24
- Resistance Level
- RDVT $52.43
- XNCR $12.63
- Average True Range (ATR)
- RDVT 1.66
- XNCR 0.57
- MACD
- RDVT -0.29
- XNCR 0.11
- Stochastic Oscillator
- RDVT 30.15
- XNCR 76.73
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.